A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Byetta (Exenatide) and Other Antidiabetic Agents

Registration

Registration

NCT01077323

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

363766

Start

2004-09

Primary completion

2008-03

Lead sponsor

AstraZeneca

Conditions

Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)

Interventions

DRUG:exenatide; DRUG:Other antidiabetic therapies; OTHER:No diabetes therapy

Results posted

TRUE

Registered primary outcomes

• Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During "Current Use" Period) - Time on Drug Analysis [43 months]
• Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (Among "Recent Use" Period) - Time on Drug Analysis [43 months]
• Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During "Past Use" Period) - Time on Drug Analysis [43 months]